Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans
BE Strauer, M Brehm, T Zeus, M Köstering… - Circulation, 2002 - Am Heart Assoc
Background— Experimental data suggest that bone marrow–derived cells may contribute to
the healing of myocardial infarction (MI). For this reason, we analyzed 10 patients who were …
the healing of myocardial infarction (MI). For this reason, we analyzed 10 patients who were …
Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: the IACT Study
BE Strauer, M Brehm, T Zeus, T Bartsch… - Journal of the American …, 2005 - jacc.org
Objectives : Stem cell therapy may be useful in chronic myocardial infarction (MI); this is
conceivable, but not yet demonstrated in humans. Background : After acute MI, bone marrow-…
conceivable, but not yet demonstrated in humans. Background : After acute MI, bone marrow-…
Lipid lowering therapy in cardiovascular disease: From myth to molecular reality
…, L Busch, H Richter, T Hohlfeld, T Zeus… - Pharmacology & …, 2020 - Elsevier
Lipid-lowering therapy is one major cornerstone of medical treatment of cardiovascular disease
in order to modulate atherosclerosis. Statins, ezetimibe and novel PCSK9-inhibitors are …
in order to modulate atherosclerosis. Statins, ezetimibe and novel PCSK9-inhibitors are …
The BALANCE Study: clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial …
M Yousef, CM Schannwell, M Köstering, T Zeus… - Journal of the American …, 2009 - jacc.org
Objectives : The aim of this study was to investigate the quantitative amount of improvement
of ventricular hemodynamic status, geometry, and contractility as well as the long-term …
of ventricular hemodynamic status, geometry, and contractility as well as the long-term …
Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical/echocardiographic data from a global prospective …
…, V Geist, P Della Bella, A Colombo, T Zeus… - … : journal of EuroPCR …, 2017 - europepmc.org
Aims The global, prospective AMPLATZER Amulet observational study documents real-world
periprocedural, transoesophageal echocardiographic (TEE) and clinical outcomes from left …
periprocedural, transoesophageal echocardiographic (TEE) and clinical outcomes from left …
Rivaroxaban reduces arterial thrombosis by inhibition of FXa-driven platelet activation via protease activated receptor-1
…, T Hoffmann, B Levkau, T Hohlfeld, T Zeus… - Circulation …, 2020 - Am Heart Assoc
Rationale: A reduced rate of myocardial infarction has been reported in patients with atrial
fibrillation treated with FXa (factor Xa) inhibitors including rivaroxaban compared with vitamin …
fibrillation treated with FXa (factor Xa) inhibitors including rivaroxaban compared with vitamin …
Transplantation of autologous mononuclear bone marrow stem cells in patients with peripheral arterial disease (the TAM-PAD study)
T Bartsch, M Brehm, T Zeus, G Kögler, P Wernet… - Clinical Research in …, 2007 - Springer
Objectives For patients with severe, chronic limb ischemia in many cases interventional or
surgical treatment is not possible anymore. In the past, both intramuscular and intraarterial …
surgical treatment is not possible anymore. In the past, both intramuscular and intraarterial …
Device-related thrombus after left atrial appendage closure: data on thrombus characteristics, treatment strategies, and clinical outcomes from the EUROC-DRT …
…, JE Nielsen-Kudsk, S Afzal, T Zeus… - Circulation …, 2021 - Am Heart Assoc
Background: Left atrial appendage closure is an established therapy in patients with atrial
fibrillation. Although device-related thrombosis (DRT) is relatively rare, it is potentially linked to …
fibrillation. Although device-related thrombosis (DRT) is relatively rare, it is potentially linked to …
The latest evolution of the Medtronic CoreValve system in the era of transcatheter aortic valve replacement: matched comparison of the Evolut PRO and Evolut R
…, A Polzin, R Westenfeld, M Kelm, T Zeus… - JACC: Cardiovascular …, 2018 - jacc.org
Objectives : The aim of this study was to investigate the hemodynamic and clinical performance
of the Evolut PRO compared with its direct predecessor, the Evolut R. Background : …
of the Evolut PRO compared with its direct predecessor, the Evolut R. Background : …
Transcatheter aortic valve replacement with next-generation self-expanding devices: a multicenter, retrospective, propensity-matched comparison of Evolut PRO …
…, L Conradi, M Barbanti, GG Stefanini, T Zeus… - Cardiovascular …, 2019 - jacc.org
Objectives The aim of this study was to compare transcatheter aortic valve replacement (TAVR)
with the Acurate neo (NEO) and Evolut PRO (PRO) devices. Background The NEO and …
with the Acurate neo (NEO) and Evolut PRO (PRO) devices. Background The NEO and …